Infusion of High Doses of Undiluted Etoposide Through Central Venous Catheters During Preparation for Bone Marrow Transplantation

1990 ◽  
Vol 8 (1) ◽  
pp. 13-16 ◽  
Author(s):  
Richard J. Creger Pharm ◽  
Robert M. Fox ◽  
Hillard M. Lazarus
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Central Venous Catheters ◽  
Central Venous ◽  
High Doses

scholarly journals Insertion of central venous catheters in children undergoing bone marrow transplantation: is there a platelet level for a safe procedure?

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Ahmed Elgendy ◽  
Ahmed M. Ismail ◽  
Eslam Elhawary ◽  
Ahmed Badran ◽  
Mohammed Ramadan El-Shanshory
Keyword(s):  
Bone Marrow ◽  
Platelet Count ◽  
Bone Marrow Transplantation ◽  
Postoperative Complications ◽  
Marrow Transplantation ◽  
Central Venous Catheters ◽  
Bleeding Complications ◽  
Safe Procedure ◽  
Central Venous ◽  
Platelet Transfusions

Abstract Background Bone marrow transplantation (BMT) is a therapeutic procedure for the management of several hematological diseases and malignancies in pediatric population. Central venous catheters (CVCs) play a pivotal role during the process of BMT. The aim of this study was to compare the complications of CVCs placements in children undergoing BMT with platelet levels above and below 50,000/μL and also to detect if there is a platelet count for a safe insertion. This prospective study included all children who had placements of tunneled CVCs during BMT at our hospital between March 2017 and March 2020. Procedures were divided into two groups accordingly to preoperative platelet counts (above and below 50,000/μL). Data were compared between both groups regarding postoperative complications including bleeding or catheter-related blood stream infections (CRBSIs). Results Forty-six CVC insertions were performed in 40 patients. There were 20 procedures below 50,000/μL (median 27,500; range 5000–42,000) inserted with perioperative platelet transfusions, and their postoperative levels were median 59,500/μL, range 18,000–88,000. Allogeneic BMT was adopted in 39 patients (97.5%). Beta thalassemia major was the commonest indication (21/40, 52.5%), followed by acute lymphocytic leukemia in six patients (15%). There were nine postoperative complications (bleeding n = 2 and CRBSIs n = 7) encountered in all placements. Four of them occurred in insertions below 50,000/μL (two bleeding complications that managed conservatively, and two CRBSIs). Post-procedural morbidities regarding bleeding or CRBSIs did not differ significantly between both groups (p value = 0.099 and 0.695, respectively). Conclusions Postponement of CVC insertions in thrombocytopenic children due to the fear of potential complications seems unwarranted, as it has no significant impact on the morbidity. Placements of such catheters can be safe under cover of perioperative platelet transfusions irrespective of the preoperative platelet count.

Clinical Experience With Minocycline and Rifampin-Impregnated Central Venous Catheters in Bone Marrow Transplantation Recipients: Efficacy and Low Risk of Developing Staphylococcal Resistance

2003 ◽  
Vol 24 (12) ◽  
pp. 961-963 ◽  
Author(s):  
Ioannis Chatzinikolaou ◽  
Hend Hanna ◽  
Linda Graviss ◽  
Gassan Chaiban ◽  
Cheryl Perego ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Clinical Experience ◽  
Marrow Transplantation ◽  
Bloodstream Infections ◽  
Central Venous Catheters ◽  
Low Risk ◽  
Clinical Use ◽  
Retrospective Evaluation ◽  
Central Venous

AbstractIn this retrospective evaluation of the 4-year clinical use of minocycline and rifampin-impregnated catheters in bone marrow transplantation (BMT) patients, we report low risk of development of staphylococcal resistance to the antibiotics coating the catheters and efficacy in preventing primary staphylococcal bloodstream infections.

Central venous catheters (CVC) in bone marrow transplantation and leukemia patients

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 8269-8269 ◽  
Author(s):  
B. Barman ◽  
R. Ghosh ◽  
A. Mondal ◽  
K. Saha ◽  
S. Mukhopadhyay ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Central Venous Catheters ◽  
Central Venous

Acute/relapsing experimental autoimmune encephalomyelitis: Induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation

1999 ◽  
Vol 5 (1) ◽  
pp. 017-021 ◽  
Author(s):  
Dimitrios Karussis ◽  
Urania Vourka-Karussis ◽  
Rachel Mizrachi-Koll ◽  
Oded Abramsky
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Experimental Autoimmune Encephalomyelitis ◽  
Marrow Transplantation ◽  
Autoimmune Encephalomyelitis ◽  
High Doses ◽  
Specific Tolerance ◽  
Experimental Autoimmune

Experimental autoimmune encephalomyelitis (EAE) is an inducible autoimmune disease widely used as a model of the acute/relapsing stage of multiple sclerosis. We have previously shown that treatment of EAE-mice with high doses of cyclophosphamide (CY) (350 mg kg), followed by syngeneic bone marrow transplantation (SBMT), completely abrogates the clinical paralytic signs and even prevents the appearance of new relapses in the chronic-relapsing model of the disease. In the present study we examined whether this treatment protocol induces long term tolerance and whether this tolerance is antigen-specific. EAE was induced by immunization with spinal cord homogenate (MSCH) in complete Freund's adjuvant (CFA). The treatment with CY and SBMT was performed on day 6 post immunization. Treated and untreated mice were rechallenged with MSCH, or a non-relevant antigen (OVA) in CFA at various stages after the first paralytic attack. In contrast to previous data showing that animals recovering from acute EAE are usually refractory to re-induction of the disease, repeated injections of MSCH at different sites from the initial immunization, followed by i.v. injection of inactivated Bordetella bacteria, 2, 4 and 6 months after the initial EAE-induction, caused a severe and usually lethal relapse in all the untreated, control animals. Mice treated with CY and SBMT were resistant to all rechallenges with the same encephalitogenic inoculum. Following the second rechallenge, peripheral lymph node cells were examined in vitro for their proliferative responses to myelin antigens or to OVA. Lymphocytes obtained from CY+SBMT treated mice did not proliferate in vitro in response to myelin basic protein (MBP), but proliferated against OVA, when immunized with this antigen, after SBMT. Adoptive transfer of lymphocytes from tolerant mice to naive recipients did not transfer resistance to EAE-induction. Our results indicate that high doses of CY, followed by SBMT, induce long term antigen-specific tolerance presumably by a mechanism of clonal deletion or anergy.

scholarly journals Granulocytic sarcoma presented as a reactivation of chronic myeloid leukemia after allogenic marrow transplantation

1998 ◽  
Vol 116 (2) ◽  
pp. 1689-1691 ◽  
Author(s):  
José Salvador Rodigues de Oliveira ◽  
Maria de Lourdes Lopes Ferrari Chauffaille ◽  
Gisele Wally Braga Colleoni ◽  
Vânia Maris Morelli ◽  
Omar Magid Hauache ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Chronic Myeloid Leukemia ◽  
Marrow Transplantation ◽  
Myeloid Leukemia ◽  
Granulocytic Sarcoma ◽  
Blastic Crisis ◽  
Allogenic Bone ◽  
Allogenic Bone Marrow Transplantation ◽  
High Doses

The authors report the case of a chronic myeloid leukemia (CML) patient submitted to allogenic bone marrow transplantation, who had probably never entered complete remission. The disease was reactivated as a granulocytic sarcoma, next to a platinum plate installed to correct a tibia fracture 11 years earlier. Its final event was a myeloid Ph1+ blastic crisis that was unsuccessfully treated with high doses of sc interferon and citarabine.

Sign in / Sign up

Export Citation Format

Share Document